Absci (ABSI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.6M

Revenue (quarter)

$318,000.00

Revenue growth (year over year)

−46.37%

Gross profit (trailing twelve months)

$1.6M

Gross margin

100.00%

Net income (trailing twelve months)

−$121.1M

Net income (quarter)

−$33.2M

Net income growth (year over year)

−8.64%

Net margin

−7756.37%

Return on equity

−57.72%

EPS (trailing twelve months)

−$0.79

Book value per share

$1.43

P/E (trailing twelve months)

—

Price to book

6.34

Debt to assets

8.47%

Payout ratio

—

Dividend yield

—

Company profile

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

• Is Absci (ABSI) profitable?

  No. Absci reported a net loss of $121.1M over the trailing twelve months.

• How much revenue does Absci (ABSI) make?

  Absci generated $1.6M in revenue over the trailing twelve months, down 46.37% year over year.

• How do I buy stock in Absci (ABSI)?

  ABSI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.